New drug combo targets tough cancers in early trial

NCT ID NCT04491942

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times

Summary

This early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, or ovarian cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.